CROWELL GAYLE A 4

What Happened

• Gayle Crowell, a director of Pliant Therapeutics (PLRX), was granted derivative securities representing 70,000 shares on June 11, 2026. The grant is reported at $0.00 per share on the Form 4 (an award/grant of derivative securities rather than an open‑market purchase or sale). This is a compensation award to a director, not an immediate sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (timely).
• Type: Award/Grant of derivative securities (code A) for 70,000 shares; reported price $0.00 per share.
• Shares owned after transaction: not specified in the provided filing.
• Vesting (per filing footnote): 25% of the award vests on Oct 1, 2026, 25% on Jan 1, 2027, 25% on Apr 1, 2027, and the final 25% vests on the earlier of (i) the one‑year anniversary of the June 11, 2026 grant or (ii) the next annual meeting of stockholders, subject to continued service as a director.
• No indication in the provided data of a 10b5‑1 plan, tax withholding sale, cashless exercise, or other immediate disposition.

Context

• Director awards like this are routine compensation and do not reflect an immediate cash investment or sale. Because this is a derivative grant with staged vesting, it vests over time and requires continued service to realize full value. Purchases (insider buys) can be more directly interpreted as a bullish signal; grants and awards mainly reflect company compensation practices.